ADMA Biologics, Inc. (ADMA) compared with its closest peers (IOVA, TARS, BEAM, KOD, BCRX): P/E 13.7 vs industry 17.2. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | $4.05B | -2.5 |
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.08B | -51.6 |
| Beam Therapeutics Inc. (BEAM) | $2.93B | -34.2 |
| Kodiak Sciences Inc. (KOD) | $2.50B | -6.5 |
| BioCryst Pharmaceuticals, Inc. (BCRX) | $2.47B | 6.5 |
| Hemab Therapeutics Holdings, Inc. (COAG) | $2.25B | — |
| Vericel Corporation (VCEL) | $2.15B | 112.5 |
| Recursion Pharmaceuticals, Inc. (RXRX) | $1.77B | -2.8 |
| Taysha Gene Therapies, Inc. (TSHA) | $1.75B | -16.1 |
| Vir Biotechnology, Inc. (VIR) | $1.55B | -1.9 |
| Stock P/E | 13.7 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -36.5% |
| vs Industry | -20.1% |
ADMA overview · ADMA earnings · ADMA financials · ADMA KPIs · ADMA investor relations · ADMA ownership · ADMA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.